Citius Pharmaceuticals Inc. [NASDAQ: CTXR] closed the trading session at $2.28 on 06/03/21. The day’s price range saw the stock hit a low of $2.18, while the highest price level was $2.31. The company report on May 25, 2021 that Citius Pharmaceuticals Selected to Receive Best Poster Award at the International Society for Cell and Gene Therapy 2021 Annual Meeting.
Poster highlighting proof-of-concept study of Citius’ iPSC-derived stem cell therapy in acute lung injury chosen for Best Poster Award at ISCT 2021 from among 336 posters selected from,400 abstracts submitted.
Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on anti-infective products in adjunct cancer care, unique prescription products and stem cell therapy, announced that it has received the Best Poster Award at the prestigious International Society for Cell and Gene Therapy (ISCT) 2021 Annual Meeting.
The stocks have a year to date performance of 123.53 percent and weekly performance of 0.88 percent. The stock has been moved at 125.74 percent over the last six months. The stock has performed -4.60 percent around the most recent 30 days and changed 28.81 percent over the most recent 3-months.
If compared to the average trading volume of 6.86M shares, CTXR reached to a volume of 3465188 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Citius Pharmaceuticals Inc. [CTXR]:
The Average True Range (ATR) for Citius Pharmaceuticals Inc. is set at 0.17 The Price to Book ratio for the last quarter was 1.75, with the Price to Cash per share for the same quarter was set at 0.75.
CTXR stock trade performance evaluation
Citius Pharmaceuticals Inc. [CTXR] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 0.88. With this latest performance, CTXR shares dropped by -4.60% in over the last four-week period, additionally plugging by 125.74% over the last 6 months – not to mention a rise of 130.30% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CTXR stock in for the last two-week period is set at 56.26, with the RSI for the last a single of trading hit 55.22, and the three-weeks RSI is set at 56.44 for Citius Pharmaceuticals Inc. [CTXR]. The present Moving Average for the last 50 days of trading for this stock 2.01, while it was recorded at 2.31 for the last single week of trading, and 1.42 for the last 200 days.
Citius Pharmaceuticals Inc. [CTXR]: An insightful look at the core fundamentals
Return on Total Capital for CTXR is now -59.46, given the latest momentum, and Return on Invested Capital for the company is -59.42. Return on Equity for this stock declined to -60.46, with Return on Assets sitting at -48.24. When it comes to the capital structure of this company, Citius Pharmaceuticals Inc. [CTXR] has a Total Debt to Total Equity ratio set at 4.02. Additionally, CTXR Total Debt to Total Capital is recorded at 3.86, with Total Debt to Total Assets ending up at 3.09. Long-Term Debt to Equity for the company is recorded at 3.03, with the Long-Term Debt to Total Capital now at 2.91.
Reflecting on the efficiency of the workforce at the company, Citius Pharmaceuticals Inc. [CTXR] managed to generate an average of -$1,754,808 per employee.Citius Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 35.20 and a Current Ratio set at 35.20.
Earnings per share (EPS) analysis for Citius Pharmaceuticals Inc. [CTXR] stock
With the latest financial reports released by the company, Citius Pharmaceuticals Inc. posted -0.11/share EPS, while the average EPS was predicted by analysts to be reported at -0.1/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -10.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CTXR.
Citius Pharmaceuticals Inc. [CTXR]: Insider Ownership positions
There are presently around $25 million, or 13.30% of CTXR stock, in the hands of institutional investors. The top three institutional holders of CTXR stocks are: VANGUARD GROUP INC with ownership of 5,066,235, which is approximately 570.919% of the company’s market cap and around 9.14% of the total institutional ownership; BLACKROCK INC., holding 1,928,638 shares of the stock with an approximate value of $4.4 million in CTXR stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $2.25 million in CTXR stock with ownership of nearly 4548.663% of the company’s market capitalization.
Positions in Citius Pharmaceuticals Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 31 institutional holders increased their position in Citius Pharmaceuticals Inc. [NASDAQ:CTXR] by around 9,322,510 shares. Additionally, 5 investors decreased positions by around 212,121 shares, while 6 investors held positions by with 1,553,015 shares. The mentioned changes placed institutional holdings at 11,087,646 shares, according to the latest SEC report filing. CTXR stock had 19 new institutional investments in for a total of 2,963,499 shares, while 4 institutional investors sold positions of 198,221 shares during the same period.